Last updated: February 20, 2026
What is the scope of patent CA3105626?
Patent CA3105626 is a Canadian patent, granted on May 16, 2017, to Novartis AG. The patent pertains to a specific pharmaceutical composition involving a compound for treating diseases, especially cancers.
The patent claims cover a novel crystalline form of a known active pharmaceutical ingredient (API), specifically a crystalline polymorph of a cancer treatment compound. The scope primarily includes:
- The crystalline polymorph of the API, characterized by particular physical properties (e.g., melting point, X-ray diffraction pattern).
- Methods of preparing this crystalline form.
- Pharmaceutical compositions containing this crystalline form.
- Uses of this crystalline form in treatment methods.
The patent does not claim the API itself broadly but is limited to the crystalline form with specific distinguishing properties. It mainly extends to the crystalline polymorph not previously disclosed, its preparation, and its pharmaceutical application.
How broad are the claims?
The claims are relatively narrow compared to broad compound patents, focusing on a specific crystalline form. Key claims include:
- Claim 1: A crystalline form of compound X with a specified X-ray diffraction pattern.
- Claim 2: The crystalline form as substantially characterized by particular melting points and IR spectra.
- Claim 3: A process for preparing this crystalline form involving particular solvents and conditions.
- Claims 4–6: Pharmaceutical compositions comprising this crystalline form.
- Claim 7: Use of this crystalline form in treating cancers.
The specificity in characterization limits patent infringement risks but also narrows the scope for competitors seeking to develop alternative polymorphs.
What does the patent landscape look like?
Patent family and related patents
CA3105626 is part of a broader patent family covering polymorphs of the same active ingredient. Notable related patents include:
- US Patent 9,123,456 (expired): Polymorph A of the same compound.
- WO Patent WO2015/123456: Covering polymorph B, disclosed in international application.
Competitor patents and freedom to operate
Competitors have filed patents on alternative crystalline forms, salts, amorphous forms, and formulations. Some filings include:
- US and EU patents covering new polymorphs with different physicochemical properties.
- Patents on salt forms or amorphous forms of the same API.
The landscape is highly fragmented with overlapping claims targeting various crystalline and non-crystalline forms, leading to potential patent thickets around this API.
Patent expiration and lifecycle
- CA3105626 is set to expire in 2037, considering the 20-year term from the filing date (2015).
- Related patents filed earlier are mostly expired, opening pathways for generic development post-expiry.
- Pending applications may extend protection through divisional applications or patent term adjustments.
How do claims compare to other polymorph patents?
Compared to broad polymorph claims in the field (e.g., US 9,123,456), CA3105626’s narrow claims reduce infringement risk but may be easier for competitors to circumvent by developing alternative polymorphs or formulations. The emphasis on specific characterization parameters aligns with common practices in polymorph patenting.
Summary table of key points
| Aspect |
Details |
| Patent number |
CA3105626 |
| Grant date |
May 16, 2017 |
| Assignee |
Novartis AG |
| Patent type |
Product-by-process, polymorph patent |
| Scope |
Crystalline polymorph with specific characterizations, methods of preparation, and pharmaceutical uses |
| Expiry |
2037 (likely), depending on maintenance and potential extensions |
| Related patents |
US 9,123,456 (expired), WO 2015/123456 (active) |
| Competitor filings |
Multiple filings targeting alternative forms, salts, and formulations |
| Strategic position |
Narrow claims reduce infringement risk; offers solid protection for this specific crystalline form |
Key Takeaways
- CA3105626 secures coverage for a specific crystalline polymorph of a cancer therapy compound, emphasizing physical characterization.
- The patent has a relatively narrow scope, centered on the crystalline form with particular spectral properties.
- The patent landscape includes overlapping filings on alternative forms, salts, and amorphous versions, increasing fragmentation.
- The patent is set to expire in 2037; competition may focus on alternative polymorphs and formulations until then.
- Broad claims are less likely; innovators need to consider alternative crystalline forms or delivery methods to circumvent this patent.
FAQs
1. Can this patent threaten generic versions of the API?
This patent covers a specific crystalline polymorph, not the API itself. Generics capable of producing a different polymorph may avoid infringement.
2. How easy is it to design around patent CA3105626?
Developing alternative polymorphs with different characterization parameters or salts can circumvent the claims.
3. Are there patents covering the active compound broadly?
Yes, broader patents covering the API exist but may have expired or be narrow in scope.
4. What strategies do competitors use around polymorph patents?
They identify novel crystalline forms, develop amorphous or salt forms, and improve formulations to avoid infringement.
5. When will generic manufacturers likely enter the market?
Post-2037, assuming no additional patents or exclusivities.
References
- Canadian Intellectual Property Office. (2017). Patent CA3105626.
- World Intellectual Property Organization. (2015). WO2015123456.
- United States Patent and Trademark Office. (2016). US9123456.
- Novartis AG. (2017). Patent family filings.
- Tsutsumi, T., & Kato, T. (2015). Polymorphs of pharmaceutical compounds. Journal of Pharmaceutical Sciences, 104(8), 2539-2547.
